Emergence and Expansion of the SARS-CoV-2 Variant B.1.526 Identified in New York
Preprint — published as 10.1038/s41586-021-03908-2 · Paper page
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Recent months have seen surges of SARS-CoV-2 infection across the globe with considerable viral evolution 1-3 . Extensive mutations in the spike protein may threaten efficacy of vaccines and therapeutic monoclonal antibodies 4 . Two signature mutations of concern are E484K, which plays a crucial role in the loss of neutralizing activity of antibodies, and N501Y, a driver of rapid worldwide transmission of the B.1.1.7 lineage. Here, we report the emergence of variant lineage B.1.526 that contains E484K and its alarming rise to dominance in New York City in early 2021. This variant is partially or completely resistant to two therapeutic monoclonal antibodies in clinical use and less susceptible to neutralization by convalescent plasma or vaccinee sera, posing a modest antigenic challenge. The B.1.526 lineage has now been reported from all 50 states in the US and numerous other countries. B.1.526 rapidly replaced earlier lineages in New York upon its emergence, with an estimated transmission advantage of 35%. Such transmission dynamics, together with the relative antibody resistance of its E484K sub-lineage, likely contributed to the sharp rise and rapid spread of B.1.526. Although SARS-CoV-2 B.1.526 initially outpaced B.1.1.7 in the region, its growth subsequently slowed concurrent with the rise of B.1.1.7 and ensuing variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“L5F, T95I, D253G, (L452R*), E484K, D614G, and A701V are important spike protein substitutions that may impart reduced susceptibility to MAb’s treatments along with reduced neutralization capacity by post-vaccination sera [45].”
From Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe (2022) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“The Iota variant was first identified in New York state.In June 2021, it had a prevalence of 5-10% in the USA but remained rare outside the USA 154 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa015 · Cited by 16,873
Fetal Cardiac Rhabdomyoma: A Case Report
Suwardewa, T. G. A., Negara, I. S., Kusuma, A. J., Wiradnyana, A., Surya, R., & Tunas, I. (2016) · doi:10.15562/bmj.v5i3.346 · Cited by 12,286 · cited 1×
“2 that also harbors E484K, have been documented (8, 9).”
BackgroundNextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Self-citationGISAID: Global initiative on sharing all influenza data – from vision to reality
Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology
Rambaut, A., Holmes, E. C., O’Toole, Á., Hill, V., McCrone, J. T., Ruis, C., du Plessis, L., & Pybus, O. G. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0770-5 · Cited by 2,543
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · cited 12×
“Each reaction plate included 8 control wells, 5x106 and 5x103 copies of 413 WA-1 (wild type), UK variant and South African variant, which were generated by PCR to match 414 the variant sequences, and 2 wells with water as no template controls (NTC).”
BackgroundInfluentialAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Self-citationCross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · cited 1×
“2B shows that D253G resides in the antigenic supersite within the N-terminal domain (15), which is a target for neutralizing antibodies (16), whereas the E484K is situated at the RBD interface with the cellular receptor ACE2.”
BackgroundSelf-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246 · cited 1×
“This case is reminiscent of reported examples of extensive intra-host evolution due to persistent SARS-CoV-2 infection in immunocompromised individuals (17, 18).”
BackgroundTreeTime: Maximum-likelihood phylodynamic analysis
Sagulenko, P., Puller, V., & Neher, R. A. (2018) · Virus Evolution · doi:10.1093/ve/vex042 · Cited by 1,186
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · doi:10.1101/2021.04.22.440932 · Cited by 730
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Rakshit, P., Singh, S., Abraham, P., Panda, S., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9071542 · Cited by 730
Avanzato, V. A., Matson, M. J., Seifert, S. N., Pryce, R., Williamson, B. N., Anzick, S. L., Barbian, K., Judson, S. D., Fischer, E. R., Martens, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.049 · Cited by 716
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636
Self-citationIncreased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization
(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626
Cerutti, G., Guo, Y.-C., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E., Yu, J., Bahna, F., Bimela, J. S., et al. (2021) · bioRxiv · doi:10.1101/2021.01.10.426120 · Cited by 539 · cited 1×
“2B shows that D253G resides in the antigenic supersite within the N-terminal domain (15), which is a target for neutralizing antibodies (16), whereas the E484K is situated at the RBD interface with the cellular receptor ACE2.”
BackgroundSelf-citationAl-Kodmany, K. M. (2020) · The Urban Book Series · doi:10.1525/fsr.2005.17.4.277 · Cited by 531
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519
Self-citationMassive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR
Smyrlaki, I., Ekman, M., Lentini, A., Rufino de Sousa, N., Papanicolaou, N., Vondracek, M., Aarum, J., Safari, H., Muradrasoli, S., Rothfuchs, A. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18611-5 · Cited by 457
Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 452
Temporal signal and the phylodynamic threshold of SARS-CoV-2
Duchene, S., Featherstone, L., Haritopoulou-Sinanidou, M., Rambaut, A., Lemey, P., & Baele, G. (2020) · Virus Evolution · doi:10.1093/ve/veaa061 · Cited by 384 · cited 1×
“pandemic (1), at least three major variants of concern have emerged over the past two months (24).”
BackgroundSerial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions
Ali, S. T., Wang, L., Lau, E. H. Y., Xu, X.-K., Du, Z., Wu, Y., Leung, G. M., & Cowling, B. J. (2020) · Science · doi:10.1126/science.abc9004 · Cited by 331
Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
Washington, N. L., Gangavarapu, K., Zeller, M., Bolze, A., Cirulli, E. T., Schiabor Barrett, K. M., Larsen, B. B., Anderson, C., White, S., Cassens, T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.052 · Cited by 329
Freed, N. E., Vlková, M., Faisal, M. B., & Silander, O. K. (2020) · Biology Methods and Protocols · doi:10.1093/biomethods/bpaa014 · Cited by 267
nCoV-2019 sequencing protocol v1
Quick, J. (2020) · doi:10.17504/protocols.io.bbmuik6w · Cited by 231
Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation, Brazil
Nonaka, C. K. V., Franco, M. M., Gräf, T., de Lorenzo Barcia, C. A., de Ávila Mendonça, R. N., de Sousa, K. A. F., Neiva, L. M. C., Fosenca, V., Mendes, A. V. A., de Aguiar, R. S., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2705.210191 · Cited by 192 · cited 1×
“2 that also harbors E484K, have been documented (8, 9).”
BackgroundNovel SARS-CoV-2 Variant in Travelers from Brazil to Japan
Fujino, T., Nomoto, H., Kutsuna, S., Ujiie, M., Suzuki, T., Sato, R., Fujimoto, T., Kuroda, M., Wakita, T., & Ohmagari, N. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2704.210138 · Cited by 177
Goudsmit, J., de Ronde, A., Ho, D. D., & Perelson, A. S. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5662-5664.1996 · Cited by 115
Self-citationCovid-19: New UK variant may be linked to increased death rate, early data indicate.
Iacobucci, G. (2021) · BMJ · doi:10.1136/bmj.n230 · Cited by 113 · cited 1×
“seemingly more transmissible and possibly more virulent (5-7).”
BackgroundNovavax offers first evidence that COVID vaccines protect people against variants
Callaway, E., & Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-00268-9 · Cited by 107 · cited 5×
“Each reaction plate included 8 control wells, 5x106 and 5x103 copies of 413 WA-1 (wild type), UK variant and South African variant, which were generated by PCR to match 414 the variant sequences, and 2 wells with water as no template controls (NTC).”
ResultInfluentialWashington, N., Gangavarapu, K., Zeller, M., et al. (2021) · medRxiv · doi:10.1101/2021.02.06.21251159 · Cited by 106 · cited 1×
“seemingly more transmissible and possibly more virulent (5-7).”
BackgroundZucman, N., Uhel, F., Descamps, D., Roux, D., & Ricard, J.-D. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab129 · Cited by 92
Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant
Thorne, L. G., Bouhaddou, M., Reuschl, A.-K., Zuliani-Alvarez, L., Polacco, B., Pelin, A., Batra, J., Whelan, M. V. X., Ummadi, M., Rojc, A., et al. (2021) · doi:10.1101/2021.06.06.446826 · Cited by 91
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
West, A. P., Wertheim, J. O., Wang, J. C., Vasylyeva, T. I., Havens, J. L., Chowdhury, M. A., Gonzalez, E., Fang, C. E., Di Lonardo, S. S., Hughes, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.14.431043 · Cited by 50
Miller, E. H., Zucker, J. E., Castor, D., Annavajhala, M. K., Sepulveda, J. L., Green, D. A., Whittier, S., Scherer, M. L., Medrano, N., Sobieszczyk, M. E., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab003 · Cited by 48 · cited 1×
“S1 and Methods in Supplement) in clinical samples known to be positive for SARS-CoV-2 and stored in the Columbia University Biobank, and patient information was extracted from the COVID-Care database (13).”
MethodSelf-citationNovavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa
Wadman, M. (2021) · Science · doi:10.1126/science.abg8101 · Cited by 37
The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
Lasek-Nesselquist, E., Lapierre, P., Schneider, E., George, K. S., & Pata, J. (2021) · medRxiv · doi:10.1101/2021.02.26.21251868 · Cited by 37
Freed, N. E., Vlková, M., Faisal, M. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.28.122648 · Cited by 27
Eisenberg, M. (2018) · Oxford Scholarship Online · doi:10.1093/oso/9780199731404.003.0031 · Cited by 18 · cited 1×
“These finding are worrisome in light of recent reports that two vaccine trials showed a substantial drop in efficacy in South Africa ( 11, 12 ).”
Cardinal, D. J. (1993) · Cited by 7
Cited by
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009
Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636
“The major culprit is the E484K mutation, which has emerged independently in over 50 lineages, including in B.1.526 that we (Annavajhala et al., 2021) and others (West et al., 2021) have identified in New York recently.”
InfluentialSelf-citationSARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
Metadata
- Authors
- Annavajhala, M. K., Mohri, H., Wang, P., Nair, M., Zucker, J. E., Sheng, Z., Gomez-Simmonds, A., Kelley, A. L., Tagliavia, M., Huang, Y., Bedford, T., Ho, D. D., & Uhlemann, A.-C.
- ORCID
- Publisher
- openRxiv
- Published
- 2021-02-25
- PMC
- PMC7924303
- References
- 20
- Type
- Preprint
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.